Latest News
BioMarin completes Alesta Therapeutics acquisition
2 September 2026 - Rare disease biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) confirmed on Tuesday that it has completed the acquisition of Alesta Therapeutics, a clinical-stage biotechnology company focused on developing novel oral...
BioViva receives US patent for Klotho gene therapy targeting age-related cognitive decline
2 September 2026 - Biotechnology company BioViva USA Inc announced on Tuesday the issuance of US Patent No. 12,564,646, titled 'Treatment of Age-Related Cognitive Decline Using Genetically Modified Viral Vectors'.This patent covers the use ...
AstraZeneca completes global licence agreement for Zegfrovy
1 September 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Tuesday it has completed its exclusive global licence agreement with China-based Dizal Pharmaceutical Co., Ltd (SSE: 688192) for Zegfrovy (sunvozerti...
AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU for first-line HER2-positive metastatic breast cancer
1 September 2026 - British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) on Tuesday announced European Commission approval for Enhertu (trastuzumab de...
NeuroSense reveals strategy to advance PrimeC toward potential ALS approval
1 September 2026 - NeuroSense Therapeutics Ltd (NASDAQ:NRSN), a late-clinical stage biotechnology company developing novel treatments for neurodegenerative diseases, announced on Monday a redesigned development plan for PrimeC in amyotrophic lateral ...